GlassScriptPhysician profile
Nora Gashi
NPI 1871744474
$1,481.36
in general payments reported to CMS, 2019-2025
20 companies · $512 in 2025
The $512 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $579 · 2020: $13.95 · 2022: $150 · 2024: $227 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $738.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $222.82 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Biotronik INC. | $167.53 | 2019 | |
| Janssen Pharmaceuticals, INC | $150.13 | 2022 | |
| Lilly USA, LLC | $148.59 | 2024-2025 | Zepbound, Mounjaro |
| Portola Pharmaceuticals, LLC | $125.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $121.93 | 2019 | |
| Boston Scientific Corporation | $120.98 | 2019 | |
| Exact Sciences Corporation | $61.41 | 2024-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $56.40 | 2025 | Veozah |
| Abbvie INC. | $55.00 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $49.60 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Abiomed | $48.59 | 2024 | Impella |
| Medtronic, INC. | $29.17 | 2025 | Tyrx |
| Alnylam Pharmaceuticals INC. | $22.12 | 2025 | Onpattro |
| Takeda Pharmaceuticals U.S.A., INC. | $21.05 | 2024 | Trintellix |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $18.35 | 2019 | |
| Currax Pharmaceuticals LLC | $16.94 | 2024 | Contrave |
| Merck Sharp & Dohme LLC | $16.89 | 2025 | Capvaxive, Gardasil 9 |
| Mirum Pharmaceuticals, INC. | $14.68 | 2024 | Cholbam |
| Mallinckrodt Enterprises LLC | $14.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nora Gashi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.